公开(公告)号：US20230227577A1

公开(公告)日：2023-07-20

申请号：US17997907

申请日：2021-05-05

Applicant: Oncorus, Inc.

Inventor： Gholamreza HASSANZADEH GHASSABEH ,  Lorena LERNER ,  Sonia FEAU ,  Christophe QUÉVA

IPC: C07K16/30 ,  C12N15/63 ,  C07K16/28 ,  A61P35/00

CPC classification number: C07K16/3023 ,  C12N15/63 ,  C07K16/2809 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/52 ,  C07K2317/31

Abstract: The present disclosure provides anti-DLL3 binding constructs, such as anti-DLL3 single domain antibodies, as well as polynucleotide encoding the same. Further provided are multispecific binding constructs comprising the DLL3 binding domains described herein and polynucleotides encoding the same. Methods of production of the anti-DLL3 binding constructs and their use in the treatment of cancer are also provided herein.

公开(公告)号：US20200224220A1

公开(公告)日：2020-07-16

申请号：US16630990

申请日：2018-07-13

Applicant: ONCORUS, INC.

Inventor： Mitchell H. FINER ,  Edward M. KENNEDY ,  Lorena LERNER

IPC: C12N15/88 ,  C12N15/11 ,  C12N15/63 ,  C12N7/00

Abstract: The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.

公开(公告)号：US20220117902A1

公开(公告)日：2022-04-21

申请号：US17418465

申请日：2020-01-03

Applicant: ONCORUS, INC.

Inventor： Lorena LERNER ,  Edward M. KENNEDY ,  Mitchell H. FINER ,  Christophe QUÉVA

IPC: A61K9/51 ,  C12N7/00 ,  A61K35/768 ,  A61P35/00

Abstract: The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.

公开(公告)号：US20210403950A1

公开(公告)日：2021-12-30

申请号：US17293153

申请日：2019-11-13

Applicant: ONCORUS, INC.

Inventor： Mitchell H. FINER ,  Edward KENNEDY ,  Lorena LERNER

IPC: C12N15/86 ,  A61K9/51 ,  A61K35/768 ,  A61P35/00

Abstract: The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.

公开(公告)号：US20200206285A1

公开(公告)日：2020-07-02

申请号：US16633653

申请日：2018-07-26

Applicant: ONCORUS, INC.

Inventor： Mitchell H. FINER ,  Lorena LERNER ,  Christophe QUÉVA ,  Edward KENNEDY

IPC: A61K35/763 ,  C12N7/00 ,  C12N15/86

Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.

公开(公告)号：US20230416308A1

公开(公告)日：2023-12-28

申请号：US17999582

申请日：2021-05-28

Applicant: Oncorus, Inc.

Inventor： Lorena LERNER ,  Edward M. KENNEDY ,  Jennifer S. LEE

IPC: C07K14/005 ,  C12N15/86 ,  C07K14/55 ,  C07K14/54 ,  C07K16/28 ,  C07K14/52 ,  A61K9/127 ,  A61P35/00 ,  A61K39/125

CPC classification number: C07K14/005 ,  A61K2039/86 ,  C12Y304/23016 ,  C07K14/55 ,  C07K14/54 ,  C07K16/28 ,  C07K16/2809 ,  C07K14/522 ,  A61K9/127 ,  A61P35/00 ,  C07K14/5434 ,  C07K14/523 ,  A61K39/125 ,  C12N2770/32052 ,  C12N2770/32043 ,  C12N2770/32071 ,  C07K2319/50 ,  C07K2319/21 ,  C07K2317/622 ,  C07K2317/31 ,  C07K2317/569 ,  C12N15/86

Abstract: The disclosure relates to oncolytic virus derived replicons and capsidation of the same. The disclosure also relates to the incorporation of one or more transgenes encoding payload molecules into the replicon. The disclosure further relates to the encapsulation of the replicon and/or recombinant RNA molecules encoding oncolytic viruses into particles and the use of the replicon and/or particles for the treatment and prevention of cancer.

公开(公告)号：US20230241140A1

公开(公告)日：2023-08-03

申请号：US18165770

申请日：2023-02-07

Applicant: Oncorus, Inc.

Inventor： Mitchell H. FINER ,  Lorena LERNER ,  Christophe QUÉVA ,  Edward KENNEDY

IPC: A61K35/763 ,  C12N7/00 ,  C12N15/86

CPC classification number: A61K35/763 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16632 ,  C12N2710/16643

Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.

公开(公告)号：US20220380735A1

公开(公告)日：2022-12-01

申请号：US17767132

申请日：2020-10-09

Applicant: Oncorus, Inc.

Inventor： Edward M. KENNEDY ,  Lorena LERNER ,  Christophe QUEVA ,  Craig A. STRATHDEE ,  Jennifer S. LEE

IPC: C12N7/00 ,  C12N15/113 ,  C12N15/86

Abstract: The present disclosure provides dual viruses capable of producing a primary virus and a secondary virus, and dual oncolytic viruses capable of producing a primary oncolytic virus and a secondary oncolytic virus.